BMRN BioMarin Pharmaceutical Inc.

89.87
-0.66  -0.73%
Previous Close 90.53
Open 90.50
Price To book 5.87
Market Cap 15.46B
Shares 171,987,000
Volume 1,290,223
Short Ratio 5.92
Av. Daily Volume 1,138,530

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 interim data released July 2016. Update due in December 2016. Phase 2b to be initiated 2H 2017.
BMN 270
Hemophilia A
Approved Feb 14 2014
Vimizim (GALNS)
(MPS IVA) Morquio A Syndrome
Phase 2 updated data released October 2016. Phase 3 trial to be initiated end of 2016.
Vosoritide
Achondroplasia
Phase 3 data released March 2016. Primary endpoint hit. Key secondary endpoint missed. NDA (BLA) filing to be filed 1Q 2017.
PEG-PAL
Phenylketonuria (PKU)
Program terminated June 2016
Reveglucosidase alfa (BMN 701)
Pompe Disease
CRL issued January 14 2016
Kyndrisa
Duchenne Muscular Dystrophy (DMD)
PDUFA date extended by three months to April 27 2017
Cerliponase alfa
Batten Disease

Latest News

  1. JANA Partners Made Massive New Pharma Investments in Q4
  2. Blog Coverage Celgene's Multiple Sclerosis Drug Reported Positive Phase-III Results
  3. Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc.
  4. BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?
  5. BioMarin Announces 11 Presentations at 13th Annual WORLDSymposium™ 2017
  6. Gilead Sciences & Bristol Myers: Two Wrongs Make a Right?
  7. BioMarin to Attend Three Investor Conferences in 1Q17
  8. Your Guide To 2017's Emerging Pharmaceuticals Catalysts
  9. BioMarin sues to stop generic version of its $90K-a-year drug
  10. BioMarin to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call and Webcast on Thursday, February 23 at 4:30pm ET
  11. Coverage initiated on BioMarin Pharm by Morgan Stanley
  12. BioMarin's Hemophilia Candidate Included in PRIME Initiative
  13. BioMarin Receives Access to Priority Medicines (PRIME) Regulatory Support from EMA for BMN 270 Gene Therapy in Hemophilia A
  14. 4 Top Biotech Stocks With Big Upcoming Catalysts
  15. BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : January 30, 2017
  16. Is BioMarin (BMRN) Well Poised for Growth in 2017?
  17. We’re in the year of the biotech buyout, and here are five prime targets
  18. Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential
  19. BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : January 18, 2017
  20. Top Stocks to Buy Now That the 21st Century Cures Act Has Passed